Castleark Management LLC Boosts Holdings in Charles River Laboratories International, Inc. $CRL

Castleark Management LLC lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 22.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,435 shares of the medical research company’s stock after buying an additional 7,190 shares during the period. Castleark Management LLC’s holdings in Charles River Laboratories International were worth $6,803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Jones Financial Companies Lllp increased its stake in Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after acquiring an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Charles River Laboratories International during the 1st quarter worth $418,000. American Century Companies Inc. grew its holdings in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the period. Brown Advisory Inc. increased its position in shares of Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Charles River Laboratories International by 3.9% during the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after purchasing an additional 3,198 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 0.1%

Charles River Laboratories International stock opened at $226.38 on Monday. The firm has a market capitalization of $10.90 billion, a P/E ratio of -60.21, a P/E/G ratio of 2.52 and a beta of 1.40. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $238.85. The stock’s fifty day simple moving average is $198.80 and its 200-day simple moving average is $187.36.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same period last year, the business posted $2.34 earnings per share. Charles River Laboratories International’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CRL has been the subject of several research analyst reports. Morgan Stanley increased their target price on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Evercore restated an “outperform” rating and set a $220.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.